Literature DB >> 24755203

Arterial stiffness, antiphospholipid antibodies, and pulmonary arterial hypertension in systemic lupus erythematosus.

Ji Hyun Lee1, Kyoung Im Cho2.   

Abstract

BACKGROUND: The aim of this study is to evaluate the role of arterial stiffness in pulmonary arterial hypertension (PAH) in systemic lupus erythematosus (SLE) patients and its relationship with antiphospholipid antibody (aPL).
METHODS: Measurement of brachial ankle pulse wave velocity (baPWV), carotid arterial stiffness, and pulmonary vascular resistance (PVR) was performed in 51 patients with SLE. PAH was diagnosed if the pulmonary artery systolic pressure was >40mmHg. Information concerning SLE duration, medication, and serum autoantibodies was recorded. SLE activity was assessed by the SLE disease activity index (SLEDAI).
RESULTS: aPL was present in 10 patients (20%), and PAH was detected in 6 patients (12%). The prevalence of Raynaud's phenomenon, baPWV, positive aPL, and titers of IgG anticardiolipin antibody (aCL) were increased in SLE with PAH; however, no difference was found in inflammatory markers, disease duration, and SLEDAI compared to SLE without PAH. Carotid artery deformation and right ventricular function were reduced in patients with PAH (all p<0.05). Carotid artery circumferential strain (r=0.34, p=0.021), radial strain (r=-0.30, p=0.045), and baPWV (r=0.46, p=0.001) showed significant correlation between IgG aCL. Univariate and multiple regression analysis revealed that the only significant independent predictors of the presence of PAH were baPWV, carotid artery stiffness, and IgG aCL.
CONCLUSION: Arterial stiffness might contribute to the pathogenesis of PAH related to SLE as well as aPLs. Furthermore, the significant association of aPL with arterial stiffness suggests its important role in PAH with SLE.
Copyright © 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arterial stiffness; Pulmonary hypertension; Systemic lupus erythematosus

Mesh:

Substances:

Year:  2014        PMID: 24755203     DOI: 10.1016/j.jjcc.2014.02.030

Source DB:  PubMed          Journal:  J Cardiol        ISSN: 0914-5087            Impact factor:   3.159


  6 in total

Review 1.  Pulmonary hypertension associated with antiphospholipid antibody: Call for a screening tool?

Authors:  Rukma Parthvi; Rutuja R Sikachi; Abhinav Agrawal; Ajay Adial; Abhinav Vulisha; Sameer Khanijo; Arunabh Talwar
Journal:  Intractable Rare Dis Res       Date:  2017-08

Review 2.  Prevalence of pulmonary hypertension in systemic lupus erythematosus: a meta-analysis.

Authors:  Tian-Tian Lv; Peng Wang; Shi-Yang Guan; Hong-Miao Li; Xiao-Mei Li; Bin Wang; Hai-Feng Pan
Journal:  Ir J Med Sci       Date:  2017-12-18       Impact factor: 1.568

Review 3.  Pulmonary hypertension in antiphospholipid syndrome.

Authors:  Stéphane Zuily; Denis Wahl
Journal:  Curr Rheumatol Rep       Date:  2015-01       Impact factor: 4.592

Review 4.  Systemic lupus erythematosus and pulmonary arterial hypertension: links, risks, and management strategies.

Authors:  Konstantinos Tselios; Dafna D Gladman; Murray B Urowitz
Journal:  Open Access Rheumatol       Date:  2016-12-20

5.  Outcomes and Risk Factors of Systolic Pulmonary Artery Pressure Progression in Patients with Systemic Rheumatic Diseases: Follow-up Results from a Korean Registry.

Authors:  Mi Ryoung Seo; Jina Yeo; Hee Jung Ryu; Hyo-Jin Choi; Kwang-Pil Ko; Han Joo Baek
Journal:  Arch Rheumatol       Date:  2020-04-27       Impact factor: 1.472

6.  Exploration of the Shared Gene Signatures and Molecular Mechanisms Between Systemic Lupus Erythematosus and Pulmonary Arterial Hypertension: Evidence From Transcriptome Data.

Authors:  Menghui Yao; Chunyi Zhang; Congcong Gao; Qianqian Wang; Mengmeng Dai; Runzhi Yue; Wenbo Sun; Wenfang Liang; Zhaohui Zheng
Journal:  Front Immunol       Date:  2021-07-15       Impact factor: 7.561

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.